Coherus BioSciences and Amgen have reportedly settled a patent lawsuit over biosimilar adalimumab.
Coherus BioSciences and Amgen have reportedly settled a patent lawsuit over biosimilar adalimumab.
Bloomberg Law said the notice of agreement, approved this week in federal court in Wilmington, Delaware, gave no further details. In the suit, Coherus claimed Amgen’s adalimumab biosimilar, Amgevita, referencing AbbVie’s Humira, infringes 4 patents for its own biosimilar version of the same reference.
Amgen launched Amgevita in Europe in October 2018, but the product is made in the United States, a fact that gave rise to the suit. According to Coherus’ original complaint, US production constitutes infringement on 3 of Coherus’ US patents, and this infringement warrants an award of damages.
Later, Coherus amended its complaint to include alleged infringement of a fourth patent, directed to the stable aqueous pharmaceutical composition of adalimumab.
In the United States, no biosimilar adalimumab will launch until 2023 on the basis of numerous patent settlements, though Amgen holds the earliest launch date of any biosimilar adalimumab: January 31.
Recently, Alexandra Valenti, JD, associate at Goodwin, discussed the case with The Center for Biosimilars® in an interview. According to Valenti, the case was interesting from a strategic standpoint: “Amgen is set to be the first adalimumab biosimilar launch in the United States in January of 2023. Coherus won’t launch until December 2023 under its agreement, and so the suit presents and interesting scenario because all Coherus can really hope to achieve is to keep 1 of 7 potential biosimilar competitors off the market,” said Valenti. “It is an interesting case from that perspective to understand what Coherus is hoping to achieve with the suit.”
Valenti said that she sees the potential for more such suits among different biosimilar developers over various formulations, processes, and other product features, but “the question will be how successful will they be and what will their effects be on the market landscape.”
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient With MS Sues J&J Over ERISA Violation
February 14th 2024After a patient with multiple sclerosis (MS) was forced to pay exorbitant out-of-pocket costs for a brand name medication when she could’ve gotten a generic for way less, the patient filed a class action complaint against her employer, Johnson & Johnson (J&J), for violating the Employee Retirement Income Security Act of 1974 (ERISA).
Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars
January 11th 2024As Regeneron gears up for a legal battle with biosimilar competitors for its reference aflibercept, CareFirst files a lawsuit against Johnson & Johnson for restricting biosimilar ustekinumab competition; Celltrion and Accord BioPharma file with the FDA to approve their respective biosimilar candidates.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).